NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
VUITY (pilocarpine hydrochloride) by AbbVie is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Approved for presbyopia. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUITY is a pilocarpine hydrochloride ophthalmic solution approved in 2021 for presbyopia and vaginal dryness. It is a cholinergic parasympathomimetic agent that stimulates muscarinic receptors to increase secretion by exocrine glands and produce miosis and accommodation effects. The drug works by enhancing natural physiological responses in target tissues.
$0.283MPart D
Peak13.0 years to LOEVUITY is in peak lifecycle with modest Part D claims; the brand team is likely focused on market penetration and indication expansion in a narrow specialty segment.
Mechanism of Action
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on VUITY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.